Peter Smits, ESC 2021 – High Bleeding Risk After Coronary Stenting
Dr Peter Smits (Interventional Cardiologist, Maasstad Hospital, Rotterdam, The Netherlands) kindly shared his thoughts on the major challenges in the treatment of patients at high bleeding risk after coronary stenting, with an overview of the recent key clinical trials involving percutaneous coronary intervention with stent deployment in patients at high bleeding risk, from the virtual ESC Congress 2021.
Questions
- What are the major challenges in the management of patients at high bleeding risk after coronary stenting? (0.12)
- How has the identification of patients at high bleeding risk improved in recent years and what challenges remain? (0.30)
- Could you give us an overview of the recent key clinical trials involving percutaneous coronary intervention (PCI) with stent deployment in patients at high bleeding risk? (1.41)
- What factors should be considered when selecting antiplatelet and antithrombotic strategies for patients following PCI? (3.59)
- What questions remain unanswered and what does the future hold? (4.47)
Speaker disclosures: Dr Peter Smits wishes to declare from the last 12 months: receipt of institutional research grants from Abbott Vascular and SMT, receipt of consultancy and speaker’s fees from Terumo, Abbott Vascular, Abiomed, Microport and AstraZeneca.
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Dr Peter Smits as a highlight of ESC 2021, August 2021.
